Breast highlights
Paper picks and regulatory news, newest first.
October 2026
- Can we safely combine radiotherapy with antibody-drug conjugates—or does the specific ADC change the risk?
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Publication pick. Radiotherapy & Oncology. October 15, 2026.
- Is precision breast cancer care entering a new era, or are complexity, biomarker uncertainty, and unequal access holding it back?
Advances in Systemic Treatment of Breast Cancer (Review)
Publication pick. NEJM. October 12, 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
- FDA NEWS: HER2CLIMB-05 Update
FDA NEWS: HER2CLIMB-05 Update
Regulatory news. FDA. October 7, 2026.
- immunotherapy while others rapidly develop resistance?
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
Publication pick. CellPress. October 7, 2026.
- Could targeting both ER and PI3K–AKT–mTOR pathways help overcome endocrine resistance?
Giredestrant plus Everolimus in Advanced Breast Cancer
Publication pick. NEJM. October 3, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.